News & Insights

Person

Date

  • Filter by dates

Active filters:

17.03.2023

GESSEL honoured in Chambers Europe 2023

Chambers and Partners have announced the results of their Europe 2022 ranking. We are proud to point out that our firm has strengthened its position i...

News
NEW!
GESSEL honoured in Chambers Europe 2023

14.07.2023

We advised Kredyt Inkaso S.A. on its public offering of bonds with a total value of 18 million pln

Kredyt Inkaso S.A. conducted a public offering of N1-series bonds worth 18 million pln, already the second issue made under a program of issuance up to a total of 100 mi...

Case studies
We advised Kredyt Inkaso S.A. on its public offering of bonds with a total value of 18 million pln

05.07.2023

We advised WSE-listed Bioceltix S.A. on a non-brokered public offering of the Company’s shares

We advised WSE-listed Bioceltix S.A. on a non-brokered public offering of the Company's shares carried out under the accelerated book-building (ABB) procedure and a rela...

Case studies
We advised WSE-listed Bioceltix S.A. on a non-brokered public offering of the Company’s shares

26.06.2023

We advised WSE-listed Pure Biologics S.A. on a PLN 12 million financing transaction

We advised WSE-listed Pure Biologics S.A. in a transaction to raise PLN 12 million in financing from a new investor, ACRX Investments Ltd. The transaction was executed ...

Case studies
We advised WSE-listed Pure Biologics S.A. on a PLN 12 million financing transaction

23.06.2023

We advised WSE-listed Genomtec S.A. on a non-brokered public offering

We advised WSE-listed Genomtec S.A. on a non-brokered public offering of the company's shares carried out under an accelerated bookbuilding procedure (ABB) and a related...

News
We advised WSE-listed Genomtec S.A. on a non-brokered public offering

Do you want to be up to date?

Subscribe to the newsletter!

23.06.2023

We advised the WSE-listed Genomtec S.A. on its prospect-free IPO

We advised the WSE-listed Genomtec S.A. on a prospect-free public offering of the company's shares carried out under the accelerated bookbuilding procedure (ABB) and a r...

Case studies
We advised the WSE-listed Genomtec S.A. on its prospect-free IPO

22.06.2023

4 awards for GESSEL in Ranking of Law Firms 2023 of the Rzeczpospolita daily

21 RANKING OF LAW FIRMs 2023 of the Rzeczpospolita daily brought us 4 awards and great pride in the achievements of the many people who make up the GESSEL law firm. I...

News
4 awards for GESSEL in Ranking of Law Firms 2023 of the Rzeczpospolita daily

20.03.2023

GESSEL advises Urteste S.A. on a public placement of new issue shares and on transfer of its shares

GESSEL advises Urteste S.A. on a public placement of new issue shares and on transfer of its shares from the NewConnect alternative trading system to the main floor of t...

Case studies
GESSEL advises Urteste S.A. on a public placement of new issue shares and on transfer of its shares

17.03.2023

GESSEL honoured in Chambers Europe 2023

Chambers and Partners have announced the results of their Europe 2022 ranking. We are proud to point out that our firm has strengthened its position in Band 1 of the Cor...

News
GESSEL honoured in Chambers Europe 2023

23.12.2022

GESSEL advises Pure Biologics S.A., a company listed on the Warsaw Stock Exchange

GESSEL supported Pure Biologics S.A. and its shareholders in preparation of a prospect-less public share offering via the accelerated book building process and execution...

Case studies
GESSEL advises Pure Biologics S.A., a company listed on the Warsaw Stock Exchange

18.11.2022

GESSEL advises Cavatina Holding S.A. on another public bond placement valued at PLN 16.5 mln

Cavatina Holding S.A. is continuing its planned sequence of bond offerings, bringing to the market P2022D series bonds with a value of PLN 16.5 mln – which, in conjuncti...

News
GESSEL advises Cavatina Holding S.A. on another public bond placement valued at PLN 16.5 mln